IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression - Hagemann, Sven; Misiak, Danny; Bell, Jessica L.; Fuchs, Tommy; Lederer, Marcell I.; Bley, Nadine; Hämmerle, Monika; Ghazy, Ehab; Sippl, Wolfgang; Schulte, Johannes H.; Hüttelmaier, Stefan (Molecular cancer, 2023)
Keywords: 17q gain; Animal models; Animals; BIRC5 (survivin); BTYNB; Cancer; Cell Line, Tumor; Chromosome 17; Chromosome 19; Development and progression; Gene expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes; Genes, myc; Genetic aspects; Genetic engineering; Genomes; Humans; IGF2BP1; Infant; Latency; Malignancy; Medical prognosis; Mice; MicroRNAs; Mivebresib; Molecular modelling; MYCN; N-Myc Proto-Oncogene Protein - genetics; N-Myc Proto-Oncogene Protein - metabolism; Neoplasm Recurrence, Local - genetics; Neuroblastoma; Neuroblastoma - drug therapy; Neuroblastoma - genetics; Neuroblastoma - metabolism; Neuroblastoma cells; Oncogenes; Phox2b protein; Post-transcription; Protein binding; Regression analysis; Solid tumors; Stem cells; Survival analysis; Survivin; Synteny; Therapeutic targets; Transcriptomics; Transgenes; Tumors; Hong Kong China; China; BTYNB; 17q gain; MYCN; PDX; RNA-binding protein (RBP); IGF2BP1; YM-155; Mivebresib; Neuroblastoma; BIRC5 (survivin); Transgenic mouse model